Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.

Martina Kaurinovic Konstantina DelliAna-Mae E JonkAnouschka BiswanaCarin L E HazenbergGoda ChoiMarco R de GrootLinde M MorsinkArjan Vissink Mar Bellido

Published in: Clinical oral investigations (2022)

The oral mucosa of SR-cGVHD patients is likely to improve after 4 and 12 weeks of ruxolitinib treatment. Symptom severity at baseline does not affect the response of the oral mucosa.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
smoking cessation
drug induced